Tests intensive versus liberal phosphate targets in adults on dialysis for kidney failure
Compares two blood phosphate targets in adults with kidney failure receiving dialysis.
Key facts
- Who runs it
- The University of Queensland
- Where
- Calgary, Edmonton, Halifax, Kingston, London, Longueuil, Montreal, North York, Oakville, Orillia, Oshawa, Ottawa, Québec, Red Deer, Regina, Richmond Hill, Scarborough Village, Sherbrooke, Toronto, Vancouver, and Winnipeg, CanadaSee the 33 sitesAlso in 8 other countries, 93 sites
- Trial code
- Registry title
- Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)
- Status
- Recruiting
- People taking part
- 3,600 people, planned
- Started
- 10 Dec 2019
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Liberal phosphate target
- Intensive phosphate target
- Record updated
- 26 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with end-stage kidney disease who have been on dialysis for at least 3 months and take a medicine that lowers phosphate. It compares a high and a low blood phosphate target.
- Age
- 45 years or older, or 18 years or older if you have diabetes.
- Sex
- All sexes can join.
- Disease stage
- End-stage kidney disease treated with haemodialysis or peritoneal dialysis for at least 3 months.
- Earlier treatment
- Must currently take at least one phosphate-lowering medicine, at any dose.
Main reasons for not taking part
- A kidney transplant is planned and scheduled
- Another serious illness that may cause death within the next 6 months, in the treating doctor's view
- Taking part in another study likely to change blood phosphate levels
- Not able to give informed consent
This trial only enrols participants on dialysis. The registry sentence this rests on: ESKD on haemodialysis or peritoneal dialysis, for at least 3 months,
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Age ≥45 years, or Age ≥18 years with diabetes,
- ESKD on haemodialysis or peritoneal dialysis, for at least 3 months,
- Currently prescribed at least one phosphate-lowering medication at any dose
- Able to provide informed consent
Who cannot take part
- Elective kidney transplantation scheduled,
- Concomitant major illness / comorbidity that may result in death in the next 6 months in the view of the treating physician,
- Participation in an interventional study that is likely to affect serum phosphate concentration
Where in Canada
Also in 8 other countries, 93 sites
- Foothills Hospital/ U of CalgaryCalgary, CanadaContact: Louis GirardTaking people
- Alberta Health ServicesEdmonton, CanadaContact: David CollisterTaking people
- Dalhousie UniversityHalifax, CanadaContact: Karthik TennankoreTaking people
- Queen's UniversityKingston, CanadaContact: Samuel SilverTaking people
- London Health Sciences CentreLondon, CanadaContact: Matthew WeirTaking people
- The Charles Lemoyne HospitalLongueuil, CanadaContact: Dominic Poirier, DrTaking people
- CHUMMontreal, CanadaContact: William BeaubienTaking people
- Hôpital Maisonneuve-RosemontMontreal, CanadaContact: Annie-Claire Nadeau-FredetteTaking people
- Jewish General HospitalMontreal, CanadaContact: Daniel BlumTaking people
- McGill University Health CentreMontreal, CanadaContact: Rita SuriTaking people
- Sacre Coeur HospitalMontreal, CanadaContact: Remi GoupilTaking people
- Sunnybrook Health Sciences CentreNorth York, CanadaContact: Ayodele Odutayo, DrTaking people
- Oakville Trafalgar Memorial HospitalOakville, CanadaContact: Danny SapirTaking people
- Orillia Soldier's Memorial HospitalOrillia, CanadaContact: Daniel Tascona, DrTaking people
- Lakeridge HealthOshawa, CanadaContact: Andrew SteeleTaking people
- The Ottawa HospitalOttawa, CanadaContact: Swapnil HiremathTaking people
- CHU de Quebec-Universite LavalQuébec, CanadaContact: Fabrice Mac-WayTaking people
- Red Deer Hospital;Red Deer, CanadaContact: Sandeep BrarTaking people
- Prairie Vascular Research Inc.Regina, CanadaContact: Bhanu Prasad, DrTaking people
- Mackenzie HealthRichmond Hill, CanadaContact: Ron WaldTaking people
- Scarborough Hospital NetworkScarborough Village, CanadaContact: Paul TamTaking people
- Centre Hospitalier Universitaire de SherbrookeSherbrooke, CanadaContact: Martin Plaisance, DrTaking people
- Centre hospitalier universitaire de Sherbrooke (CHUS)Sherbrooke, CanadaContact: Martin PlaisanceTaking people
- Humber River HospitalToronto, CanadaContact: Gihad NesrallahTaking people
- Michael Garron HospitalToronto, CanadaContact: Nausheen SiddiquiTaking people
- St. Joseph's Healthcare HamiltonToronto, CanadaContact: Michael Walsh, DrTaking people
- St. Joseph's Healthcare TorontoToronto, CanadaContact: Joanna SasalTaking people
- St. Michael's HospitalToronto, CanadaContact: Ron Wald, DrTaking people
- Trillium Health PartnersToronto, CanadaContact: Vincent KiTaking people
- University Health Network - University of TorontoToronto, CanadaContact: Charmaine LokTaking people
- St. Paul's HospitalVancouver, CanadaContact: Mercedech KiaiiTaking people
- Vancouver General HospitalVancouver, CanadaContact: Ron WaldNo longer taking part
- St. Boniface General HospitalWinnipeg, CanadaContact: Alex Meraz-Munoz, DrTaking people
About the trial
What the trial wants to find out
During end-stage kidney disease, clinical guidelines suggest reducing elevated phosphate levels in the blood. However, the effect of lowering blood phosphate levels on important patient-centred outcomes has never been tested. This trial will evaluate whether compared to high levels, lowering blood phosphate levels would reduce death or major events due to heart disease, improve physical health, and be cost-effective.
The 2 groups in the trial
- Liberal phosphate targetExisting treatment, for comparison
Liberal serum phosphate target of 2.0 to 2.5 mmol/L.
- Intensive phosphate targetTreatment being tested
Intensive serum phosphate target of ≤1.50 mmol/L.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Investigator-initiated, International, Multi-centre, Prospective, Randomized, Open-label, Parallel-group, Superiority, and Pragmatic Large Simple Trial (LST) to Determine Whether the Currently Recommended Strategy of Intensive Reduction of Serum Phosphate Concentration Towards the Normal Level Results in Significant Patient-centred Benefits in End-stage Kidney Disease (ESKD) Patients Receiving Dialysis.
- Plain-language title
- Tests intensive versus liberal phosphate targets in adults on dialysis for kidney failureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).The Cochrane database of systematic reviews, 2025
- The Pathologic Actions of Phosphate in CKD.Kidney360, 2025
- Record updated
- 26 August 2026